Real-world safety of rapid 30-minute intravenous isatuximab infusion in multiple myeloma: results from the largest published cohort

To evaluate the safety profile of a rapid 30-minute intravenous isatuximab infusion in patients with multiple myeloma.

Study Design: Descriptive, retrospective, multicenter study across 9 Spanish hospitals, including patients with confirmed multiple myeloma who received at least one rapid intravenous isatuximab infusion.
Data Collection: Demographic, clinical, treatment, and safety data were collected, with infusion-related reactions graded per CTCAE v5.0.

103 patients included, median age 66 years, 54.4% female.
1,344 rapid 30-minute infusions administered with only 1 recorded infusion-related reaction (IRR).
Per-patient IRR rate was 0.97% and per-infusion rate was 0.074%.
21 out of 22 patients with prior IRRs completed the rapid protocol without reverting to standard rate.
Estimated 1,008 hours of cumulative day-hospital chair time savings.

Rapid 30-minute intravenous isatuximab demonstrates an excellent safety profile in a real-world setting, including in patients with prior IRRs.

Retrospective design may lead to information bias and underreporting of mild IRRs.
Missing data were not imputed.

The findings support the feasibility of a rapid infusion protocol for isatuximab in multiple myeloma treatment.